Muhammed SEZGİN, MERVE AYDIN TERZİOĞLU, FARUK KARAKEÇİLİ, Aytekin ÇIKMAN, Barış GÜLHAN, YUSUF KEMAL ARSLAN

Bruselloz Hastalarında Asimetrik Dimetilarjinin (ADMA) Düzeylerinin Araştırılması

Amaç: Asimetrik dimetilarginin (ADMA), nitrik oksit sentazın (NOS) ana endojen inhibitörüdür. NOS, konak savunmasında ve vasküler yapının sürdürülmesinde önemli rol oynamaktadır. Yüksek ADMA düzeylerinin endoteldis fonksiyonu ile ilişkili olduğu ve çeşitli hastalıklarda rol aldığı gösterilmiştir. Brucellaspp.’nin neden olduğu zoonoz bir hastalık olan bruselloz, vaskülopati olarak kendini gösterebilmektedir. Ancak, bruselloz ile ADMA arasındaki ilişki ile ilgili yeterli veri bulunmamaktadır. Çalışmamızın amacı bruselloz hastalarında ve kontrol grubunda ADMA düzeyinin araştırılmasıdır. Yöntemler: Çalışmamıza 40 akut bruselloz hastası ve 40 sağlıklı gönüllü alındı. Bruselloz hastalarında ve sağlıklı gönüllülerde serum ADMA düzeyleri İnsan ADMA ELISA kiti ile üretici firma önerileri doğrultusunda araştırıldı. Katılımcıların fiziki muayeneleri yapılarak, cinsiyet, yaş ve ikamet adreslerini içeren demografik karakteristikleri ve laboratuvar test sonuçları kayıt altına alındı. Verilerin değerlendirilmesinde IBM SPSS 20 istatistik paket programı kullanıldı. İstatistiksel anlamlılık düzeyi (p

Investigation of Asymmetric Dimethylarginine (ADMA) Levels in Patients with Brucellosis

Objective: Asymmetric dimethylarginine (ADMA) is the main endogenous inhibitor of nitric oxide synthase (NOS). NOS plays an important role in host defense and the maintenance of vascular stracture. High ADMA levels have been associated with endothelial dysfunction and have been implicated in a variety of diseases. Brucellosis is a zoonotic disease caused by Brucellaspp, which can be manifested as vasculopathy. However, there are no sufficient data regarding the relationship between ADMA and brucellosis. The aim of our study was to investigate ADMA levels in brucellosis patients and control group. Methods: Our study enrolled 40 healthy volunteers and 40 patients with acute brucellosis. Serum ADMA levels in brucellosis patients and healthy volunteers were investigated with the Human ADMA ELISA kit according to the manufacturer's recommendation. Physical examinations of the participants were carried out and the demographic characteristics including the gender, age and residence addresses and the laboratory test results were recorded. IBM SPSS 20 statistical package program was used to evaluate the data. Statistical significance level (p

PDF

___

1. Böger RH, Ron ES. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev. 2005; 10: 14-23.
2. Böger RH. The emerging role of asymmetric dimethyarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003; 59: 824-33.
3. Cooke JP. ADMA: its role in vascular disease. Vasc Med. 2005; 10: 11-7.
4. Sitar ME, Kayacelebi AA, Beckmann B, Kielstein JT, Tsikas D. Asymmetric dimethylarginine (ADMA) in human blood: effects of extended haemodialysis in the critically ill patient with acute kidney injury, protein binding to human serum albumin and proteolysis by thermolysin. Amino Acids. 2015; 47: 1983-93.
5. Teerlink T. ADMA metabolism and clearance. Vasc Med. 2005; 10: 73-81.
6. Tain YL, Hsu CN. Toxic Dimethylarginines: Asymmetric Dimethlyarginine (ADMA) and Symmetric Dimethylarginine (SDMA). Toxins (Basel). 2017; 9: 92.
7. Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl. 2003; 4: 41-51.
8. Gwida M, Al Dahouk S, Melzer F, et all. Brucellosis – regionally emerging zoonotic disease? Croat Med J. 2010; 51: 289-95.
9. El-Koumi MA, Afify M, Al-Zahrani SH. A prospective study of brucellosis in children: relative frequency of pancytopenia. Mediterr J Hematol Infect Dis. 2013; 5: e2013011.
10. Dede G, Dede O, Kapmaz M, Haykır Solay A, Utangaç M. Two cases of brucellosis epididymo-orchitis. Dicle Med J. 2015; 42 : 80-82.
11. Ulu-Kilic A, Metan G, Alp E. Clinical presentations and diagnosis of brucellosis. Recent Pat Antiinfect Drug Discov. 2013; 8: 34-41.
12. Dizbay M, Hizel K, Kilic S, et all. Brucella peritonitis and leucocytoclastic vasculitis due to Brucella melitensis. Braz J Infect Dis. 2007; 11: 443-44.
13. Karahocagil MK, Aslan M, Ceylan MR, et all. Serum myeloperoxidase activity and oxidative stress in patients with acute brucellosis. Clin Biochem. 2012; 45: 733-6.
14. Smith CL, Anthony S, Hubank M, Leiper JM, Vallance P. Effects of ADMA upon gene expression: an insight into the pathophysiological significance of raised plasma ADMA. PLoS Med. 2005; 2: e264.
15. Yamagishi S, Ueda S, Nakamura K, Matsui T, Okuda S. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Curr Pharm Des. 2008; 14: 2613-8.
16. Weis M, Kledal TN, Lin KY, et all. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation. 2004; 109: 500-5.
17. Karakecili F, Cikman A, Aydin M, Gulhan B. Asymmetrical dimethylarginine levels in Hepatitis B virus-positive patients. Ann Lab Med. 2018; 38: 446-9.
18. Kurz K, Teerlink T, Sarcletti M, et all. Asymmetric dimethylarginine concentrations decrease in patients with HIV infection under antiretroviral theraphy. Antivir Ther. 2012; 17: 1021-7.
19. Baranyi A, Meinitzer A, Putz-Bankuti C, et all. Asymmetric dimethylarginine responses during interferon-α-induced depression in patients with chronic hepatitis C infection. Psychosom Med. 2014; 76: 197-207.
20. Mengeloglu Z, Sünnetcioglu M, Tosun M, et al. High asymmetric dimethylaginine (ADMA) levels in patients with brucellosis. Inflammation. 2014; 37: 127-31.
21. Sahin M, Arslan C, Naziroglu M, et al. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet’s disease. Ann Clin Lab Sci. 2006; 36: 449-54.
22. Ferrero MC, Bregante J, Delpino MV, et al. Proinflammatory response of human endothelial cells to Brucella infection. Microbes Infect. 2011; 13: 852-61.
23. Aydemir S, Eren H, Tekin IO, et all. Helicobacter pylori eradication lowers serum asymmetric dimethylarginine levels. Mediators Inflamm. 2010; 2010: 685903.
24. Sunnetcioglu M, Mengeloglu Z, Baran AI, et all. Asymmetric dimethylarginine levels in patients with cutaneous anthrax: a laboratory analysis. Ann Clin Microbiol Antimicrob. 2014; 13: 12.
25. Beltrán LM, Muñoz Hernández R, de Pablo Bernal RS, et all. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection. PLoS One. 2014; 9: e90541.
26. Parlak M, Akbayram S, Doğan M, et al. Clinical manifestations and laboratory findings of 496 children with brucellosis in Van, Turkey. Pediatr Int. 2015; 57: 586-9.
27. Buzgan T, Karahocagil MK, Irmak H, et all. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. Int J Infect Dis. 2010; 14: 469-78.
28. Tanir G, Tufekci, SB, Tuygun N. Presentation, complications, and treatment outcome of brucellosis in Turkish children. Pediatr Int. 2009; 51: 114-9.